Non-profit Harm Reduction Therapeutics (HRT) announced that it has filled the first order for RiVive naloxone nasal spray, which was approved by the FDA in July 2023 as an over-the-counter medication for the treatment of opioid overdose. RiVive, which is being manufactured by Catalent at its Morrisville, North Carolina facility, will be more available more broadly in … [Read more...] about Harm Reduction announces availability of RiVive naloxone nasal spray in the US
News
Tiziana initiates Phase 2a trial of intranasal foralumab in non-active secondary-progressive MS
Tiziana Life Sciences announced the initiation of a Phase 2a study of intranasal foralumab in patients with non-active secondary-progressive multiple sclerosis (na-SPMS), with a primary endpoint of change in microglial activation as determined by PET scan. The trial will evaluate 2 doses of foralumab versus placebo and is expected to enroll 18 patients in each arm of … [Read more...] about Tiziana initiates Phase 2a trial of intranasal foralumab in non-active secondary-progressive MS
Vivaldi gets grant to fund preclinical transmission study of its DeltaFlu intranasal universal flu vaccine
Vivaldi Biosciences announced that the Flu Lab has provided a grant to fund a transmission study of the company's DeltaFLU intranasal universal influenza vaccine. According to the company, the study will evaluate the ability of DeltaFlu to protect against transmission of "broadly divergent wild-type influenza type A and B strains" among ferrets. The company noted … [Read more...] about Vivaldi gets grant to fund preclinical transmission study of its DeltaFlu intranasal universal flu vaccine
Ethris initiates Phase 1 trial of nasal and inhaled delivery of ETH47 mRNA therapy
After recently receiving authorization for a Phase 1 trial of its ETH47 mRNA therapy, Ethris has initiated the study, the company announced. The trial is expected to enroll 88 healthy participants aged 18 to 55 and will evaluate the safety, tolerability, and pharmacokinetics of both nasal and inhaled delivery of ETH47, as well as combined nasal/inhaled delivery. The … [Read more...] about Ethris initiates Phase 1 trial of nasal and inhaled delivery of ETH47 mRNA therapy
DDL 2023 highlighted novel technologies
The 34th iteration of the Drug Delivery to the Lungs (DDL) Conference, DDL 2023, drew approximately 930 OINDP specialists to the Edinburgh International Conference Centre (EICC) December 6 - 8, with more than 100 additional attendees joining online. The conference also drew support from 115 sponsors, including almost 20 new companies exhibiting for the first time. … [Read more...] about DDL 2023 highlighted novel technologies
Favorex to market Marinomed’s Carragelose nasal spray in Thailand, Malaysia, Myanmar, and the Philippines
Marinomed Biotech announced that DKSH subsidiary Favorex has acquired commercialization rights to Marinomed's Carragelose iota-carrageenan nasal spray for Thailand, Malaysia, Myanmar, and the Philippines. Earlier this year, Carragelose nasal spray was approved in Mexico, where it will be marketed as "Barlo" by M8. Perrigo markets the nasal spray in a number of … [Read more...] about Favorex to market Marinomed’s Carragelose nasal spray in Thailand, Malaysia, Myanmar, and the Philippines
Agomab announces initiation of Phase 1 trial of AGMB-447 inhaled ALK5 inhibitor
Agomab Therapeutics announced that it has initiated a Phase 1 trial of its AGMB-447 inhaled ALK5 inhibitor that is expected to enroll 76 healthy subjects and idiopathic pulmonary fibrosis (IPF) patients. According to Agomab, the IPF patients will receive AGMB-447 over a two-week period following a SAD/MAD portion of the study in healthy subjects. Agomab Chief … [Read more...] about Agomab announces initiation of Phase 1 trial of AGMB-447 inhaled ALK5 inhibitor
MDI Plus launches MDI carton that doubles as a spacer
Irish start-up MDI Plus has announced the availability of its novel metered dose inhaler carton, which can be used as a spacer. The carton/spacer includes holes in each end of the cardboard box, with an opening on one end shaped to accommodate the inhaler mouthpiece and an opening on the other end for inhalation. According to the company's web site, the carton can be … [Read more...] about MDI Plus launches MDI carton that doubles as a spacer
Oz-UK adds manufacturing line for MDIs with LGWP propellants
CRO Oz-UK has announced that it is installing a new manufacturing line for metered dose inhalers that use LGWP propellants and expects the new line to be in operation by July 2024. According to the company, the line will be able to handle both HFO-1234ze and HFA-152a solution and suspension formulations, with batch sizes of 2.5 to 10 kg. In addition to a recent … [Read more...] about Oz-UK adds manufacturing line for MDIs with LGWP propellants
Aptar Pharma opens new manufacturing facility in Mumbai
Aptar Pharma has announced the official opening of its new 7,000 sq m manufacturing facility in Mumbai, India. Aptar has been manufacturing MDI valves and pumps at the site since 2012. According to Aptar, the capabilities there "have now been expanded to offer more innovative product solutions and ensure increased manufacturing capacity to pharma customers in South … [Read more...] about Aptar Pharma opens new manufacturing facility in Mumbai